Eupraxia Pharmaceuticals, Inc. EPRX 深 沪
已收盘 02-06 16:00:00 美东时间
8.35
-0.110
-1.30%
华盛通- 最 高8.645
- 今 开8.52
- 成交量 26.50万股
- 最 低 8.22
- 昨 收 8.46
- 总市值 4.23亿
- 52周最高 9.32
- 市盈率 静 --
- 换手率 0.52%
- 52周最低 2.6801
- 委 比 -70.63%
- 总股本 5064.83万
- 历史最高 9.32
- 量 比 1.13
- 振 幅 5.02%
- 历史最低 2.20
- 每 手 1
- 风险率 1.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 阿斯麦、美光科技、SanDisk获大行上调目标价；美国银行、富国银行绩后遭多家机构下调目标价
今日重点评级关注：Benchmark：维持TNL Mediagene"投机性买入"评级，目标价从3.5美元升至14美元；康托·菲茨杰拉德：维持Eupraxia Pharmaceuticals"超配"评级，目标价从11美元升至19美元
01-16 10:04
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Eupraxia Pharma Reports 12-Week And 36-Week Tissue Health Data From Ongoing Phase 1b/2a Part Of RESOLVE Trial Evaluating EP-104GI For Treatment Of Eosinophilic Esophagitis
At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health. At lower doses, patients maintained the improvements in tissue
01-08 20:43
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
Eupraxia Pharmaceuticals announced positive results from its RESOLVE trial for EP-104GI in treating eosinophilic esophagitis (EoE). At 12 weeks, the highest dose achieved near-complete tissue health normalization, and improvements were maintained through 36 weeks at lower doses. Clinical remission was achieved by 8 weeks and sustained for 52 weeks in patients with extensive treatment coverage. No serious adverse events were reported, and the drug...
01-08 12:34
Eupraxia Pharma Announces Second Set Of 52-Week Follow Up Data From Ongoing Phase 1b/2a RESOLVE Trial Evaluating Single Administration EP-104GI For EoE Treatment
The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus far.In Cohort 6, a
2025-11-14 06:04
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
VICTORIA, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. announced its Q3 2025 financial results and business updates. Positive 52-week clinical data from the RESOLVE Trial demonstrated durable symptom and tissue responses for EP-104GI in treating eosinophilic esophagitis (EoE). The company completed an $80.5 million public offering to support clinical development and pipeline advancement. Cash reserves of $89 m...
2025-11-04 21:39
Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering
Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has provided an update. On September 2...
2025-09-30 05:06
Eupraxia Pharmaceuticals Reports Results With 8mg Dose In RESOLVE Trial; Patients In Cohort 9 Experienced The Largest Improvements In Tissue Health Outcomes And Eosinophil Reduction Observed To Date; Expands Phase 2b EP-104GI Study And Plans New GI Indication Trial In 2026
Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial.Patients in Cohort 9 experienced the largest improvements in tissue health outcomes and eosinophil reduction observed to date.RESOLVE Safety Committee and members of the Eupraxia Clinica
2025-09-30 05:03
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Eupraxia Pharmaceuticals reported positive results from Cohort 9 of its RESOLVE trial for EP-104GI, showing the highest dose (8mg per injection) achieved the greatest improvements in tissue health and eosinophil reduction without serious adverse events. The company plans to expand the Phase 2b trial, increasing patient numbers from 60 to at least 120, and initiate a new GI indication trial in early 2026. A webinar on October 1st will provide furt...
2025-09-29 21:00
Eupraxia Pharma将公开发行1270万股筹集约7000万美元
Eupraxia Pharmaceuticals（NASDAQ：EPRX）将其1270万股公开发行价格定为每股5.50美元，筹集约7000万美元。所筹资金将...
2025-09-23 23:21
